Summit Therapeutics (SMMT) Q2 2024 earnings summary

Executive summary

• Ivonescimab achieved positive Phase III data, including statistically significant PFS improvement over pembrolizumab in NSCLC, and secured first regulatory approval in China for advanced NSCLC post-EGFR TKI treatment.

• Strategic collaborations expanded, including a five-year partnership with MD Anderson and territory expansion to Latin America, Middle East, and Africa.

• All prior development on other assets was terminated since 2023, with focus now solely on ivonescimab.

• Two global Phase III trials for ivonescimab in NSCLC are enrolling, with HARMONI expected to complete enrollment in H2 2024.

• Leadership strengthened with the appointment of Dr. Mostafa Ronaghi and Jeff Huber to the board.

Financial highlights

• Cash, cash equivalents, restricted cash, and short-term investments totaled $325.8 million at June 30, 2024, up from $186.2 million at December 31, 2023, bolstered by a $200 million private placement.

• GAAP R&D expenses for Q2 2024 were $30.8 million; non-GAAP R&D expenses were $27.3 million.

• GAAP acquired IP R&D expenses were $15 million in Q2 2024, related to the Akeso license amendment and territory expansion.

• GAAP G&A expenses were $14 million; non-GAAP G&A expenses were $6.4 million in Q2 2024.

• GAAP net loss was $60.4 million ($0.09/share) in Q2 2024 and $103.9 million for H1 2024.

Outlook and guidance

• Cash runway expected to last into Q4 2025 based on current operations and planned clinical trials.

• Oncology R&D costs are expected to rise as ivonescimab development progresses.

• Company will need to raise additional capital to fund operations and repay a $100 million promissory note due April 2025; substantial doubt exists about ability to continue as a going concern without new funding.

• Completion of HARMONI Phase III trial enrollment anticipated in H2 2024.

• Additional Phase II and III data readouts expected at major conferences, including World Conference on Lung Cancer and ESMO.